Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.78 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | GALR3 | O60755 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alcohol SCHEMBL27846676 | 0.97 | TSHR (0.74) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| Alcohol SCHEMBL23702395 | 0.97 | TSHR (0.74) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| Propane SCHEMBL27531646 | 0.92 | TSHR (0.82) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| Propanol SCHEMBL5373909 | 0.90 | TSHR (0.70) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| Ethylene Glycol SCHEMBL1401169 | 0.89 | TSHR (0.78) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL21064874 | 0.88 | TSHR (1.00) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL19193 | 0.88 | — | — | |
| Butyl Alcohol SCHEMBL28312338 | 0.87 | TSHR (0.58) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| Dioxane SCHEMBL4036904 | 0.87 | TSHR (0.58) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| Isobutanol SCHEMBL5402392 | 0.86 | TSHR (0.74) | TSHRCHRM2CHRM4CHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117126573-B | Anti-fouling wear-resistant nano fluorocarbon coating and preparation method thereof | 江苏新福乐威涂料有限公司 | 2023-12-26 | — | — | CN | claimed |
| CN-117126573-A | Anti-fouling wear-resistant nano fluorocarbon coating and preparation method thereof | 江苏新福乐威涂料有限公司 | 2023-11-28 | — | — | CN | claimed |
| CN-116903624-A | Polymorphs of aminopterin and salts thereof | PTC医疗MP公司 | 2023-10-20 | — | — | CN | claimed |
| CN-113717063-B | Preparation and purification method of tulobuterol | 北京泰德制药股份有限公司 | 2023-08-08 | — | — | CN | claimed |
| CN-110248948-B | Polymorphs of aminopterin and salts thereof | PTC医疗MP公司 | 2023-07-28 | — | — | CN | claimed |
| CN-115368245-A | Preparation method of (1R, 2S) - (3, 4-difluorophenyl) cyclopropylamine hydrochloride crystal form | 上海医药工业研究院 | 2022-11-22 | — | — | CN | claimed |
| CN-107602546-B | Crystal form of compound, preparation method, composition and application thereof | 武汉朗来科技发展有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-114105847-A | Refining method of Vernakalant hydrochloride | 上海旭东海普药业有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-113717063-A | Preparation and purification method of tulobuterol | 北京泰德制药股份有限公司 | 2021-11-30 | — | — | CN | claimed |
| US-20210188856-A1 | CRYSTAL FORM OF HYDROCHLORIDE OF PYRAZOLOHETEROARYL DERIVATIVE AND PREPARATION METHOD | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD (CN) | 2021-06-24 | — | — | US | claimed |
| EP-3808745-A1 | CRYSTAL FORM OF HYDROCHLORIDE OF PYRAZOLOHETEROARYL DERIVATIVE AND PREPARATION METHOD | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2021-04-21 | — | — | EP | claimed |
| US-10899744-B2 | Crystalline form of compound suppressing protein kinase activity, and application thereof | XCOVERY HOLDINGS, INC. (US) | 2021-01-26 | — | — | US | claimed |
| CN-111819178-A | Crystal form of pyrazolo heteroaryl derivative hydrochloride and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2020-10-23 | — | — | CN | claimed |
| US-20190135792-A1 | CRYSTALLINE FORM OF COMPOUND SUPPRESSING PROTEIN KINASE ACTIVITY, AND APPLICATION THEREOF | XCOVERY HOLDINGS, INC. | 2019-05-09 | — | — | US | claimed |
| EP-3470410-A1 | CRYSTALLINE FORM OF COMPOUND SUPPRESSING PROTEIN KINASE ACTIVITY, AND APPLICATION THEREOF | XCOVERY Holding Company, LLC (CN) | 2019-04-17 | — | — | EP | claimed |
| CN-109195964-A | Inhibit crystal form and its application of protein kinase activity compound | 贝达药业股份有限公司 | 2019-01-11 | — | — | CN | claimed |
| CN-108794342-A | Ammonium carboxylate salt compound, its crystal form, amorphous substance and preparation method thereof | 武汉朗来科技发展有限公司 | 2018-11-13 | — | — | CN | claimed |
| CN-107602546-A | Crystal formation of compound and preparation method thereof, composition and application | 武汉朗来科技发展有限公司 | 2018-01-19 | — | — | CN | claimed |
| CN-105198705-A | Method for using mixed solvent to separate ethyl alcohol-acetic acid isopropyl ester azeotrope by continuous extractive distillation | UNIV JINAN | 2015-12-30 | — | — | CN | claimed |
| EP-0132506-A2 | Azeotropic fat fractionation | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 1985-02-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899744-B2 | Crystalline form of compound suppressing protein kinase activity, and application thereof | MAPKAPK5, MAP3K6, MAP3K5 | TSHR 2309/4885CHRM2 3285/4885CHRM4 3455/4885 |
| US-20190135792-A1 | CRYSTALLINE FORM OF COMPOUND SUPPRESSING PROTEIN KINASE ACTIVITY, AND APPLICATION THEREOF | MAPKAPK5, MAP3K6, MAP3K5 | TSHR 2309/4885CHRM2 3285/4885CHRM4 3455/4885 |
| US-20210188856-A1 | CRYSTAL FORM OF HYDROCHLORIDE OF PYRAZOLOHETEROARYL DERIVATIVE AND PREPARATION METHOD | CYP2F1, CYP7A1, CYP11B2 | TSHR 2375/4885CHRM2 2074/4885CHRM4 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.